WO1995006470A1 - Prevention et traitement de la maladie d'alzheimer - Google Patents

Prevention et traitement de la maladie d'alzheimer Download PDF

Info

Publication number
WO1995006470A1
WO1995006470A1 PCT/US1994/007518 US9407518W WO9506470A1 WO 1995006470 A1 WO1995006470 A1 WO 1995006470A1 US 9407518 W US9407518 W US 9407518W WO 9506470 A1 WO9506470 A1 WO 9506470A1
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
coa reductase
reductase inhibitor
alkyl
patient
Prior art date
Application number
PCT/US1994/007518
Other languages
English (en)
Inventor
Edward M. Scolnick
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU73970/94A priority Critical patent/AU7397094A/en
Publication of WO1995006470A1 publication Critical patent/WO1995006470A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Definitions

  • the present invention relates to the administration of an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to humans to lower ApoUpoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system to treat, arrest the development of and prevent the onset of Alzheimer's disease.
  • HMG-CoA reductase inhibitor including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to humans to lower ApoUpoprotein
  • Alzheimer's disease is a neurodegenerative disease of the brain leading to severely impaired cognition and functionality. This disease leads to progressive regression of memory and learned functions. Alzheimer's disease is a complex disease that affects cholinergic neurons, as well as serotonergic, noradrenergic and other central neurotransmitter systems. Manifestations of Alzheimer's disease extend beyond memory loss and include personality changes, neuromuscular changes, seizures, and occasionally psychotic features.
  • Alzheimer's disease is the most common type of dementia in the United States. Some estimates suggest that up to 47% of those older than 85 years have Alzheimer's disease. Since the average age of the population is on the increase, the frequency of Alzheimer's disease is increasing and requires urgent attention. Alzheimer's is a difficult medical problem because there are presently no adequate methods available for its prevention or treatment.
  • the first class consists of compounds that augment acetylcholine neurotransmitter function.
  • cholinergic agonists such as the antichohnesterase drugs are being used in the treatment of Alzheimer's disease.
  • physostigmine eserine
  • the administration of physostigmine has the drawback of being considerably limited by its short half-life of effect, poor oral bioavailabihty, and severe dose-limiting side-effects, particularly towards the digestive system.
  • Tacrine tetrahydroaminocridine
  • this compound may cause hepatotoxicity.
  • a second class of drugs that are being investigated for the treatment of Alzheimer's disease is neurotropics that affect neuron metabolism with little effect elsewhere. These drugs improve nerve cell function by increasing neuron metabolic activity.
  • Piracetam is a neurotropic that may be useful in combination with acetylcholine precursors and may benefit Alzheimer's patients who retain some quantity of functional acetylcholine neurons.
  • Oxiracetam is another related drug that has been investigated for Alzheimer treatment.
  • a third class of drugs include those drugs that affect brain vasculature.
  • a mixture of ergoloid mesylates is used for the treatment of dementia. Ergoloid mesylates decrease vascular resistance and thereby increase cerebral blood flow.
  • calcium channel blocking drugs including Nimodipine which is a selective calcium channel blocker that affects primarily brain vasculature.
  • miscellaneous drugs are targeted to modify other defects found in Alzheimer's disease.
  • Selegiline a monoamine oxidase B inhibitor which increases brain dopamine and norepinephrine has reportedly caused mild improvement in some Alzheimer's patients.
  • Aluminum chelating agents have been of interest to those who believe Alzheimer's disease is due to aluminum toxicity.
  • Drugs that affect behavior including neuroleptics, and anxiolytics have been employed. Side effects of neuroleptics range from drowsiness and anti cholinergic effects to extrapyramidal side effects; other side effects of these drugs include seizures, inappropriate secretion of antidiuretic hormone, jaundice, weight gain and increased confusion.
  • Anxiolytics which are mild tranquilizers, are less effective than neuroleptics, but also have milder side effects. Use of these behavior-affecting drugs, however, remains controversial.
  • Apolipoprotein E type 4 allele was more than eight times as likely to be affected with Alzheimer's disease than individuals who did not possess any copies of the Apolipoprotein E type 4 allele.
  • the protein encoded by Apolipoprotein E type 4 allele, ApoE isoform 4 has a higher avidity in vitro for ⁇ -amyloid than ApoE isoform 3.
  • Apolipoprotein E is the major apolipoprotein in the central nervous system, where it appears to be involved in nerve regeneration following injury. Apolipoprotein E is synthesized in several extra hepatic tissues, including brain, and is catabolized predominantly by the liver.
  • the present invention provides for a method of treating, arresting the development of and preventing Alzheimer's disease by regulating the amount of ApoE isoform 4 circulating in the bloodstream and in the brain, most particularly in the brain of a patient with or at risk of developing Alzheimer's disease employing an HMG-CoA reductase inhibitor selected from lovastatin and simvastatin, including the corresponding open-ring dihydroxy acid forms and the salts and esters thereof.
  • an HMG-CoA reductase inhibitor selected from lovastatin and simvastatin, including the corresponding open-ring dihydroxy acid forms and the salts and esters thereof.
  • Lovastatin (MEVACOR®), simvastatin (ZOCOR®) pravastatin (PRAVACHOL®), and fluvastatin (LESCOL®) are known cholesterol lowering agents.
  • These compounds are inhibitors of HMG-CoA reductase, which is the rate-limiting step in the biosynthesis of cholesterol.
  • Lovastatin and related compounds are disclosed in U.S. Patent No. 4,231 ,938; simvastatin and related comounds are disclosed in U.S. Patent No. 4,450,171 and U.S. Patent No. 4,346,227; pravastatin and related compounds are disclosed in U.S. Patent No. 4,346,227 and fluvastatin and related compounds such as disclosed in PCT Publication WO 84/02131.
  • the present invention provides for a method of preventing and treating Alzheimer's disease by treating a patient in need of such treatment with an HMG-CoA reductase inhibitor, including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to lower Apolipoprotein E isoform 4 (ApoE isoform 4) levels in the central nervous system.
  • an HMG-CoA reductase inhibitor including lovastatin (MEVACOR®) and simvastatin (ZOCOR®), the open-ring dihydroxy acid forms thereof, and salts and esters thereof, and pravastatin (PRAVACHOL®) and fluvastatin (LESCOL®), the closed ring lactone forms and salts and esters thereof, to lower Apolipoprotein E
  • the present invention relates to administration of an HMG- CoA reductase inhibitor to humans at risk for developing Alzheimer's disease for the purpose of preventing the onset of Alzheimer's disease.
  • the HMG-Co A reductase inhibitors which are used in the method of this invention include the compounds represented by the following structural formula (I):
  • Z is selected from:
  • R2 is selected from:
  • Ci-3 alkyl substituted with hydroxy; R3 is selected from:
  • X is NCH(CH 3 ) 2 or C(CH 2 ) 4 .
  • R4 and R ⁇ are each independently selected from hydrogen, halogen, Ci-4 alkyl, Ci-4 alkoxy and trifluoromethyl, and
  • R5, R6, R7 5 and R8 are each independently selected from hydrogen, halogen, C ⁇ _4 alkyl, and Cl-4 alkoxy; the corresponding open-ring dihydroxy acid forms thereof and pharmaceutically acceptable salts and esters thereof.
  • open-ring dihydroxy acid form and pharmaceutically acceptable salts and esters of the compound of formula (I) refers to the corresponding compound of formula (II) below:
  • RlO is selected from:
  • the pharmaceutically acceptable salts of the compounds of this invention include those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, and tetramethyl ammonium hydroxide.
  • bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)amin
  • One class of compounds of the present invention are those wherein Z is:
  • R3 is 5-OH, and a, b, c, and d are each single bonds.
  • Another subclass of compounds is characterized by R3 being 3-oxo and a and c being a double bond, or c being a double bond.
  • R3 is 7-(l-hydroxyethyl), b and d are double bonds; provided that when R2 is OH, b and d are double bonds or c is a double bond or a, b, c, and d are single bonds.
  • Another class of compounds of the present invention are those wherein Z is:
  • preventing includes not only preventing of the onset of the disease in disease-free patients, but also arresting the development of the disease in patients already manifesting symptoms of the disease, and ameliorating symptoms in patients afflicted with the disease.
  • the method of this invention is useful for treating individuals who possess one or two copies of the apolipoprotein E type 4 allele. These individuals are more likely to develop late onset and sporadic Alzheimer's disease.
  • the method of this invention is also useful in halting the progression of Alzheimer's disease in a patient who already exhibits symptoms of dementia, and ameliorating the degenerative effects of Alzheimer's disease.
  • the present invention provides for a means of lowering the levels of Apolipoprotein E isoform 4 circulating in the bloodstream and in the brain by employing an HMG-CoA reductase inhibitor of structural formula (I) the open ring dihydroxy acid forms thereof and salts and esters thereof.
  • this invention relates to the lowering of Apolipoprotein E isoform 4 circulating through the central nervous system and present in the cerebrospinal fluid.
  • Apolipoprotein E isoform 4 (“ApoE isoform 4”) is an apolipoprotein which is the gene product of the apolipoprotein E type 4 allele. Possession of one or two copies of the apolipoprotein E type 4 allele has been linked to a greatly increased risk of developing Alzheimer's disease.
  • the present invention provides for a method of decreasing circulating blood levels of ApoE isoform 4 throughout the body, including the brain. In the liver, low density lipoprotein receptors (LDL receptors) are responsible for absorbing and taking up from the bloodstream various lipoproteins including some of those containing ApoE isoform 4. LDL receptors are regulated by gene repressors derived from cholesterol which suppress the transcription of the LDL-receptor.
  • LDL receptors are regulated by gene repressors derived from cholesterol which suppress the transcription of the LDL-receptor.
  • Inhibition of cholesterol biosynthesis reduces the presence of these cholesterol-derived LDL gene repressors. This relieves the suppression of the production of the LDL receptor, leading to production of additional LDL receptors in the liver, which, in turn, remove additional ApoE containing lipoproteins from the bloodstream.
  • Reduced levels of ApoE isoform 4 in the bloodstream promotes an increase in the flux of ApoE isoform 4 from the CNS to the plasma, thus reducing the risk of, halting the development of and/or ameliorating the symptoms of Alzheimer's disease. It is also possible that these agents could work directly on the CNS to reduce ApoE levels in the brain.
  • the HMG-CoA reductase inhibitor of structural formula (I), the open-ring dihydroxy acid forms thereof, and salts and esters thereof may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers. It is usually desirable to use the oral route.
  • the compounds of structural formula (I), the open-ring dihydroxy acid forms thereof, and salts and esters thereof may be administered orally in the form of a capsule, a tablet or the like.
  • the orally administered medicament may be administered in the form of a time-controlled release vehicle, including diffusion controlled systems, osmotic devices, dissolution controlled matrices and erodible/degradable matrices.
  • Doses may be varied, depending on the age, severity, body weight and other conditions of human patients, but daily dosage for adults is within a range of from about 1 mg to 1000 mg (preferably 5 to 100 mg,) which may be given in a single dose or in two to four divided doses. Higher doses may be favorably employed as required.
  • HF high fat
  • LF low fat
  • P placebo
  • L lovastatin
  • ApoE unit is mg/dl.
  • HMG-CoA reductase inhibitors The following protocol is used to determine the effect of HMG-CoA reductase inhibitors on cerebrospinal fluid levels of ApoE in Alzheimer's patients homozygous for ApoE type 4 allele.
  • Other HMG- CoA reductase inhibitors may be substituted for simvastatin.
  • a randomized, double-blind placebo controlled, parallel- design, multicenter six week study is conducted. Approximately 30 men and women (to provide 20 patients with baseline and follow-up lumbar punctures) between the ages of 50 and 85 years with a diagnosis of sporadic or late-onset familial AD, homozygous for the ApoE4 isoform, and with a low density lipoprotein (LDL) cholesterol level greater than 100 mg/dl are recruited for participation in the study and informed consent is obtained. (Patients incapable of giving informed consent have written consent from their guardian or representative.)
  • LDL low density lipoprotein
  • Patients qualifying for entry after screening are randomized to simvastatin, 40 mg/day or placebo for six weeks.
  • a lumbar puncture will be performed prior to randomization and at Week 6 to determine cerebrospinal fluid levels of ApoE and other apolipoproteins. If the lumber puncture is judged traumatic (greater than grossly hemorrhage and greater than 50,000 RBC/mm ⁇ F), it is repeated in one week. Plasma is obtained at these time points for plasma total, LDL, HDL cholesterol and apolipoproteins including ApoE. For those patients in whom the six week lumbar puncture follow-up cannot be performed on time, a two week window is allowed (Week 4 to 8 of active treatment).
  • the primary endpoint is a comparison between simvastatin and placebo groups in the mean cerebrospinal ApoE levels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à l'administration d'un inhibiteur de la réductase HMG-CoA comprenant de la lovastatine (MEVACOR®) et de la sinvastatine (ZOCOR®), des formes acide dishydroxy à cycle ouvert ainsi que les sels et esters de ces dernières et de la pravastatine (PRAVACHOL®) ainsi que de la fluvastatine (LESCOL®), des formes lactone à cycle fermé et des sels et esters de ces dernières, à des sujets humains de manière à réduire les taux d'isoforme 4 d'apoliprotéine E(isoforme 4 ApoE) dans le système nerveux central de manière à traiter, à stopper le développement et à prévenir le commencement de la maladie d'Alzheimer.
PCT/US1994/007518 1993-08-30 1994-07-05 Prevention et traitement de la maladie d'alzheimer WO1995006470A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73970/94A AU7397094A (en) 1993-08-30 1994-07-05 Prevention and treatment of alzheimer's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11427093A 1993-08-30 1993-08-30
US11388093A 1993-08-30 1993-08-30
US114,270 1993-08-30
US113,880 1993-08-30

Publications (1)

Publication Number Publication Date
WO1995006470A1 true WO1995006470A1 (fr) 1995-03-09

Family

ID=26811581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007518 WO1995006470A1 (fr) 1993-08-30 1994-07-05 Prevention et traitement de la maladie d'alzheimer

Country Status (2)

Country Link
AU (1) AU7397094A (fr)
WO (1) WO1995006470A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047518A1 (fr) * 1997-04-17 1998-10-29 Europäisches Laboratorium für Molekularbiologie (EMBL) Utilisation d'agents hypo-cholesterolemiants pour influer sur les processus de transduction de signaux au niveau de la membrane cellulaire, dans le cadre de la prophylaxie ou du traitement de maladies associees aux prions ou de la maladie d'alzheimer
WO1999015159A2 (fr) * 1997-09-24 1999-04-01 Nova Molecular, Inc. Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
WO1999038498A1 (fr) * 1998-01-28 1999-08-05 Warner-Lambert Company Procede pour le traitement de la maladie d'alzheimer
US5955472A (en) * 1995-11-02 1999-09-21 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
WO1999048488A2 (fr) * 1998-03-23 1999-09-30 Children's Medical Center Corporation ABAISSEMENT DE LA TENEUR EN PROTEINE β-AMYLOÏDE
US6017913A (en) * 1999-05-03 2000-01-25 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO2000028981A2 (fr) * 1998-11-13 2000-05-25 Nymox Corporation Methodes de traitement, de prevention et de reduction du risque d'apparition de la maladie d'alzheimer utilisant un inhibiteur de la hmg-coa reductase
WO2001032161A2 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide
WO2001045698A1 (fr) * 1999-12-21 2001-06-28 Merck & Co. Inc. Therapie combinee pour le traitement de maladie neurodegenerative
WO2002085368A2 (fr) * 2001-04-20 2002-10-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Utilisation de composes antiradicalaires dans le traitement et la prevention de troubles de la microcirculation no-dependants
EP1366061A2 (fr) * 2001-02-05 2003-12-03 Andrx Corporation Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide
EP1370210A2 (fr) * 2001-02-07 2003-12-17 The McLean Hospital Corporation Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs
WO2004006935A1 (fr) * 2002-07-11 2004-01-22 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Utilisation de composes activant le trajet de la proteine srebp
EP1584333A2 (fr) * 1998-01-28 2005-10-12 Warner-Lambert Company LLC Utilisation d'inhibiteurs de l'acétylcoenzime A pour traiter l'Alzheimer
EP1603548A2 (fr) * 2003-02-05 2005-12-14 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
WO2005120496A2 (fr) * 2004-05-24 2005-12-22 Regents Of The University Of California Traitement de defauts d'apprentissage a l'aide d'inhibiteurs de la hmg-coa reductase
WO2005123068A2 (fr) * 2004-06-08 2005-12-29 Axonyx, Inc. Methodes de ralentissement de la progression de la maladie d'alzheimer comprenant l'administration d'un inhibiteur de la proteine precurseur de la proteine beta-amyloide et d'un inhibiteur de la hmg coa reductase
US7049058B2 (en) 1997-11-25 2006-05-23 Musc Foundation For Research Development Methods for suppressing the induction of nitric oxide synthase in a cell
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
WO2007098417A2 (fr) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation TRAITEMENT DE LA MALADIE D'ALZHEIMER AVEC DES INHIBITEURS DE LA FIXATION DE L'ApoE AU RÉCEPTEUR DE L'ApoE
US7964598B2 (en) 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
US8211922B2 (en) 2005-07-11 2012-07-03 Cortria Corporation 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US8679534B2 (en) 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
CN104188940A (zh) * 2014-09-26 2014-12-10 天津市聚星康华医药科技有限公司 一种辛伐他汀口腔速溶膜及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 96, No. 23, issued 1982, TOBERT et al., "Cholesterol-Lowering Effect of Mevinolin, an Inhibitor of 3-Hydroxy-Methylglutaryl-Coenzyme A Reductase, in Healthy Volunteers", Abstract No. 193161s; & J. CLIN. INVEST., 69(4), 913-19. *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964598B2 (en) 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
US5955472A (en) * 1995-11-02 1999-09-21 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
WO1998047518A1 (fr) * 1997-04-17 1998-10-29 Europäisches Laboratorium für Molekularbiologie (EMBL) Utilisation d'agents hypo-cholesterolemiants pour influer sur les processus de transduction de signaux au niveau de la membrane cellulaire, dans le cadre de la prophylaxie ou du traitement de maladies associees aux prions ou de la maladie d'alzheimer
US6274603B1 (en) 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
WO1999015159A2 (fr) * 1997-09-24 1999-04-01 Nova Molecular, Inc. Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
WO1999015159A3 (fr) * 1997-09-24 2000-02-17 Nova Molecular Inc Methodes permettant d'augmenter les taux d'apolipoproteine dans le traitement de maladies neurodegeneratives
JP2001517617A (ja) * 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
US7396659B2 (en) 1997-11-25 2008-07-08 Musc Foundation For Research Development Inhibitors of nitric oxide synthase to treat type 1 diabetes
US8507219B2 (en) 1997-11-25 2013-08-13 Musc Foundation For Research Development Method of treating inflammation with statins
US7049058B2 (en) 1997-11-25 2006-05-23 Musc Foundation For Research Development Methods for suppressing the induction of nitric oxide synthase in a cell
US8679534B2 (en) 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
AU762124B2 (en) * 1998-01-28 2003-06-19 Warner-Lambert Company Method for treating Alzheimer's disease
WO1999038498A1 (fr) * 1998-01-28 1999-08-05 Warner-Lambert Company Procede pour le traitement de la maladie d'alzheimer
EP1584333A2 (fr) * 1998-01-28 2005-10-12 Warner-Lambert Company LLC Utilisation d'inhibiteurs de l'acétylcoenzime A pour traiter l'Alzheimer
EP1584333A3 (fr) * 1998-01-28 2009-04-29 Warner-Lambert Company LLC Utilisation d'inhibiteurs de l'acétylcoenzime A pour traiter l'Alzheimer
JP2010047616A (ja) * 1998-03-23 2010-03-04 Childrens Medical Center Corp βアミロイドタンパク質を減少させるための方法
JP2002507564A (ja) * 1998-03-23 2002-03-12 チルドレンズ メディカル センター コーポレーション βアミロイドタンパク質を減少させるための方法
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6440387B1 (en) 1998-03-23 2002-08-27 Children's Medical Center Corporation Methods for determining risk of Alzheimer's disease
WO1999048488A2 (fr) * 1998-03-23 1999-09-30 Children's Medical Center Corporation ABAISSEMENT DE LA TENEUR EN PROTEINE β-AMYLOÏDE
WO1999048488A3 (fr) * 1998-03-23 2000-06-22 Childrens Medical Center ABAISSEMENT DE LA TENEUR EN PROTEINE β-AMYLOÏDE
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
WO2000028981A2 (fr) * 1998-11-13 2000-05-25 Nymox Corporation Methodes de traitement, de prevention et de reduction du risque d'apparition de la maladie d'alzheimer utilisant un inhibiteur de la hmg-coa reductase
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
JP2002529500A (ja) * 1998-11-13 2002-09-10 ナイモックス コーポレーション ＨＭＧＣｏＡレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法
WO2000028981A3 (fr) * 1998-11-13 2000-11-09 Nymox Corp Methodes de traitement, de prevention et de reduction du risque d'apparition de la maladie d'alzheimer utilisant un inhibiteur de la hmg-coa reductase
AU771254B2 (en) * 1998-11-13 2004-03-18 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of Alzheimer's disease using an HMG CoA reductase inhibitor
US6017913A (en) * 1999-05-03 2000-01-25 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
WO2001032161A3 (fr) * 1999-11-04 2002-03-14 Andrx Corp Methode de traitement de troubles lies au precurseur beta-amyloide
WO2001032161A2 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide
WO2001045698A1 (fr) * 1999-12-21 2001-06-28 Merck & Co. Inc. Therapie combinee pour le traitement de maladie neurodegenerative
EP1366061A2 (fr) * 2001-02-05 2003-12-03 Andrx Corporation Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide
EP1366061A4 (fr) * 2001-02-05 2006-04-26 Andrx Corp Methode de traitement de troubles de la maturation du precurseur de la proteine beta amyloide
EP1370210A2 (fr) * 2001-02-07 2003-12-17 The McLean Hospital Corporation Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs
EP1370210A4 (fr) * 2001-02-07 2004-08-18 Mclean Hospital Corp Hypocholesterolemiants utilises pour traiter les troubles psychologiques et cognitifs
US7064130B2 (en) 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
WO2002085368A2 (fr) * 2001-04-20 2002-10-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Utilisation de composes antiradicalaires dans le traitement et la prevention de troubles de la microcirculation no-dependants
WO2002085368A3 (fr) * 2001-04-20 2003-02-20 Boehringer Ingelheim Pharma Utilisation de composes antiradicalaires dans le traitement et la prevention de troubles de la microcirculation no-dependants
WO2004006935A1 (fr) * 2002-07-11 2004-01-22 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Utilisation de composes activant le trajet de la proteine srebp
EP1603548A4 (fr) * 2003-02-05 2007-10-10 Myriad Genetics Inc Composition et methode de traitement de troubles neurodegeneratifs
EP1603548A2 (fr) * 2003-02-05 2005-12-14 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
WO2005120496A2 (fr) * 2004-05-24 2005-12-22 Regents Of The University Of California Traitement de defauts d'apprentissage a l'aide d'inhibiteurs de la hmg-coa reductase
WO2005120496A3 (fr) * 2004-05-24 2006-10-12 Univ California Traitement de defauts d'apprentissage a l'aide d'inhibiteurs de la hmg-coa reductase
US8222293B2 (en) * 2004-05-24 2012-07-17 Regents of the University of Carolina Treating learning deficits with inhibitors of Hmg CoA reductase
WO2005123068A3 (fr) * 2004-06-08 2006-08-17 Axonyx Inc Methodes de ralentissement de la progression de la maladie d'alzheimer comprenant l'administration d'un inhibiteur de la proteine precurseur de la proteine beta-amyloide et d'un inhibiteur de la hmg coa reductase
WO2005123068A2 (fr) * 2004-06-08 2005-12-29 Axonyx, Inc. Methodes de ralentissement de la progression de la maladie d'alzheimer comprenant l'administration d'un inhibiteur de la proteine precurseur de la proteine beta-amyloide et d'un inhibiteur de la hmg coa reductase
US8211922B2 (en) 2005-07-11 2012-07-03 Cortria Corporation 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
US8481570B2 (en) 2005-07-11 2013-07-09 Cortria Corporation 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities
WO2007098417A3 (fr) * 2006-02-21 2007-10-18 Oklahoma Med Res Found TRAITEMENT DE LA MALADIE D'ALZHEIMER AVEC DES INHIBITEURS DE LA FIXATION DE L'ApoE AU RÉCEPTEUR DE L'ApoE
WO2007098417A2 (fr) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation TRAITEMENT DE LA MALADIE D'ALZHEIMER AVEC DES INHIBITEURS DE LA FIXATION DE L'ApoE AU RÉCEPTEUR DE L'ApoE
CN104188940A (zh) * 2014-09-26 2014-12-10 天津市聚星康华医药科技有限公司 一种辛伐他汀口腔速溶膜及其制备方法

Also Published As

Publication number Publication date
AU7397094A (en) 1995-03-22

Similar Documents

Publication Publication Date Title
WO1995006470A1 (fr) Prevention et traitement de la maladie d'alzheimer
Tobert New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
AU2003227516B2 (en) A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU680864B2 (en) Combination of a cholesterol biosynthesis inhibitor and a beta-lactam cholesterol absorption inhibitor
Yamamoto et al. Therapeutic effects of ML-236B in primary hypercholesterolemia
WO2004001002A2 (fr) Nouvelles compositions anticholesterol et methode d'utilisation de ces compositions
CN107405352A (zh) 神经活性化合物及其使用方法
Illingworth et al. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia
US5763492A (en) Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
Abedin et al. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs
Saunders et al. Lovastatin and gallstone dissolution: a preliminary study
US4355027A (en) Process and composition for treating disorders by administering piracetam and choline
Bailey et al. Anti-inflammatory drugs in experimental atherosclerosis Part 6. Combination therapy with steroid and non-steroid agents
JPH0623105B2 (ja) てんかんの発作の治療用製薬組成物
CA2426492C (fr) Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
US4153700A (en) Treatment of the acute after-effects resulting from alcohol ingestion
Duvall et al. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin–niacin combination therapy
JPH04502020A (ja) 腸内鉄吸収性を制御するための経口投与ポルフィリン類
JPH05504971A (ja) バムブテロールを含む脂質低下用医薬組成物
Hayashi et al. Preventative and therapeutic effects of AE0047 on renal injury in stroke‐prone spontaneously hypertensive rats
EP0116238A1 (fr) Compositions thérapeutiques et leur application pour améliorer la fonction cérébrale
JPH07233062A (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
US20050107465A1 (en) Composition for treating inflammatory bowel disease
Nakashima Treatment of hyperlipidemia
Tikkanen 2 Practical drug therapy for common hyperlipidaemias

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CN CZ FI GE HU JP KE KG KR KZ LK LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US US UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA